A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options begin trading today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK options ...

Merck (MRK) closed the most recent trading day at $86.39, moving -0.24% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 4.84% for the day. Meanwhile ...

MERCK & CO INC (MRK) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

But AstraZeneca stock fell in line with pharma stocks. Merck (NYSE:MRK) recently presented promising results from the Phase 3 ZENITH trial for its drug WINREVAIR, but the company's stock ...

We recently published a list of Jim Cramer Recently Talked About These 9 Stocks. In this article, we are going to take a look ...

Research analysts at Zacks Research reduced their Q1 2026 EPS estimates for shares of Merck & Co., Inc. in a research note issued to investors on Tuesday, April 1st. Zacks Research analyst S. Ganoria ...

MRK stock's annual dividend yield of ~3.4% is appealing, but given the challenges ahead, it’s not a top 5 "buy" in Big Pharma currently. In 2025, the company is guiding for revenues of $64.1bn ...

Investing isn’t easy, and given the current market volatility, retail investors are on edge, worrying about their portfolios.